Product Description
Becaplermin gel is used as part of a total treatment program to help heal certain ulcers (sores) of the foot, ankle, or leg in people who have diabetes. Becaplermin gel must be used along with good ulcer care including: removal of dead tissue by a medical professional; the use of special shoes, walkers, crutches, or wheelchairs to keep weight off the ulcer; and treatment of any infections that develop. Becaplermin cannot be used to treat ulcers that have been stitched or stapled. Becaplermin is a human platelet-derived growth factor, a substance naturally produced by the body that helps in wound healing. It works by helping to repair and replace dead skin and other tissues, attracting cells that repair wounds, and helping to close and heal the ulcer. (Sourced from: https://medlineplus.gov/druginfo/meds/a699049.html)
Mechanisms of Action: PGFRa Agonist,PGFRb Agonist
Novel Mechanism: No
Modality: Large Molecule
Route of Administration: Topical
FDA Designation: None *
Approval Status: Approved
Approved Countries: Canada | Colombia | European Medicines Agency | Germany | Greece | Hungary | India | Ireland | Italy | Jordan | Lebanon | New Zealand | Portugal | Sweden | Taiwan | United Kingdom | United States
Approved Indications: Injuries/wounds Unspecified | Wounds, Stab
Known Adverse Events: Erythema
Company: None
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|